EP4346833A1 - ((1s,9s)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl} -7,11-diazatricyclo[7.3.1.0~2,7~]trideca-2,4-dien-6-one) as a stabilizer of crys for the treatment of circadian rhythm associated diseases and disorders - Google Patents
((1s,9s)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl} -7,11-diazatricyclo[7.3.1.0~2,7~]trideca-2,4-dien-6-one) as a stabilizer of crys for the treatment of circadian rhythm associated diseases and disordersInfo
- Publication number
- EP4346833A1 EP4346833A1 EP21736769.7A EP21736769A EP4346833A1 EP 4346833 A1 EP4346833 A1 EP 4346833A1 EP 21736769 A EP21736769 A EP 21736769A EP 4346833 A1 EP4346833 A1 EP 4346833A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- cry
- treatment
- cells
- cryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027288 circadian rhythm Effects 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title claims abstract description 30
- 239000003381 stabilizer Substances 0.000 title abstract description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title abstract description 6
- 208000037765 diseases and disorders Diseases 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 45
- 102100026280 Cryptochrome-2 Human genes 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 16
- 101000855613 Homo sapiens Cryptochrome-2 Proteins 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 230000003993 interaction Effects 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000006806 disease prevention Effects 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 abstract description 27
- 102100029376 Cryptochrome-1 Human genes 0.000 abstract description 17
- 101000919351 Homo sapiens Cryptochrome-1 Proteins 0.000 abstract description 16
- 230000001404 mediated effect Effects 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 6
- LHQVLWPLUAXGTE-UHFFFAOYSA-N CCCCCCCC(C=CC=CC)=O Chemical compound CCCCCCCC(C=CC=CC)=O LHQVLWPLUAXGTE-UHFFFAOYSA-N 0.000 abstract description 3
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 71
- 108010037139 Cryptochromes Proteins 0.000 description 64
- KCYOZNARADAZIZ-CWBQGUJCSA-N 2-[(2e,4e,6e,8e,10e,12e,14e)-15-(4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-2-yl)-6,11-dimethylhexadeca-2,4,6,8,10,12,14-heptaen-2-yl]-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-6-ol Chemical compound O1C2(C)CC(O)CC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C1C=C2C(C)(C)CCCC2(C)O1 KCYOZNARADAZIZ-CWBQGUJCSA-N 0.000 description 49
- KCYOZNARADAZIZ-PPBBKLJYSA-N Cryptochrome Natural products O[C@@H]1CC(C)(C)C=2[C@@](C)(O[C@H](/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(\C)/[C@H]3O[C@@]4(C)C(C(C)(C)CCC4)=C3)/C)\C)/C)C=2)C1 KCYOZNARADAZIZ-PPBBKLJYSA-N 0.000 description 49
- KCYOZNARADAZIZ-XZOHMNSDSA-N beta-cryptochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C3OC4(C)CCCC(C)(C)C4=C3 KCYOZNARADAZIZ-XZOHMNSDSA-N 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 101710119767 Cryptochrome-2 Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 19
- 230000004110 gluconeogenesis Effects 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000051325 Glucagon Human genes 0.000 description 14
- 108060003199 Glucagon Proteins 0.000 description 14
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 14
- 229960004666 glucagon Drugs 0.000 description 14
- 102100037315 F-box/LRR-repeat protein 3 Human genes 0.000 description 13
- 101001026868 Homo sapiens F-box/LRR-repeat protein 3 Proteins 0.000 description 13
- 238000003032 molecular docking Methods 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 11
- 230000008632 circadian clock Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 231100000673 dose–response relationship Toxicity 0.000 description 11
- 230000000087 stabilizing effect Effects 0.000 description 11
- 230000006641 stabilisation Effects 0.000 description 10
- 238000011105 stabilization Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- 230000009229 glucose formation Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000002060 circadian Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229960001031 glucose Drugs 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 101150023900 G6PC1 gene Proteins 0.000 description 7
- 230000001890 gluconeogenic effect Effects 0.000 description 7
- 238000004088 simulation Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102100025399 Breast cancer type 2 susceptibility protein Human genes 0.000 description 6
- 108010075228 CLOCK Proteins Proteins 0.000 description 6
- 102000008025 CLOCK Proteins Human genes 0.000 description 6
- 102000016911 Deoxyribonucleases Human genes 0.000 description 6
- 108010053770 Deoxyribonucleases Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000029918 bioluminescence Effects 0.000 description 6
- 238000005415 bioluminescence Methods 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000001543 one-way ANOVA Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 5
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 101150078024 CRY2 gene Proteins 0.000 description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000329 molecular dynamics simulation Methods 0.000 description 4
- 238000011201 multiple comparisons test Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000010798 ubiquitination Methods 0.000 description 4
- 230000034512 ubiquitination Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 101150074181 PER2 gene Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 108091007025 FBXLs Proteins 0.000 description 2
- 102000036354 FBXLs Human genes 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- 101001073216 Homo sapiens Period circadian protein homolog 2 Proteins 0.000 description 2
- 101000862167 Homo sapiens Putative F-box/LRR-repeat protein 21 Proteins 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 101100497370 Mus musculus Cry1 gene Proteins 0.000 description 2
- 101100221993 Mus musculus Cry2 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102100035787 Period circadian protein homolog 2 Human genes 0.000 description 2
- 102100027753 Putative F-box/LRR-repeat protein 21 Human genes 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000004063 proteosomal degradation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000008454 sleep-wake cycle Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 description 1
- FGAQZLNPJNNZOY-UHFFFAOYSA-N (2z,4z,6z)-1h-diazocin-8-one Chemical compound O=C1NN=CC=CC=C1 FGAQZLNPJNNZOY-UHFFFAOYSA-N 0.000 description 1
- XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 1
- LTOSAQRHTJQRRM-UHFFFAOYSA-N 2-(chloromethyl)-8-methyl-1h-quinazolin-4-one Chemical compound N1C(CCl)=NC(=O)C2=C1C(C)=CC=C2 LTOSAQRHTJQRRM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 1
- 108010088547 ARNTL Transcription Factors Proteins 0.000 description 1
- 102000008867 ARNTL Transcription Factors Human genes 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 101710119765 Cryptochrome-1 Proteins 0.000 description 1
- 238000010499 C–H functionalization reaction Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108700011215 E-Box Elements Proteins 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 1
- 101000734572 Homo sapiens Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- XTZNCVSCVHTPAI-UHFFFAOYSA-N Salmeterol xinafoate Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21.C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 XTZNCVSCVHTPAI-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241001201507 Udea Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000007034 advanced sleep phase syndrome Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000009636 circadian regulation Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 1
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000013651 non-24-hour sleep-wake syndrome Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- WYSLOKHVFKLWOU-UHFFFAOYSA-N tert-butyl 2-[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]acetate Chemical compound C=1C=C(Cl)C=CC=1CN(CC(=O)OC(C)(C)C)CC1=CC=C([N+]([O-])=O)S1 WYSLOKHVFKLWOU-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention discloses and claims ((lS,9S)-l l- ⁇ [4-(l,3-benzodioxol-5- ylamino)-8-methyl-2-quinazolinyl]methyl ⁇ -7, 1 l-diazatricyclo[7.3.1.0-2.7 ⁇
- Pharmaceutical compositions comprising Formula I and methods for the preparation of Formula I are also disclosed and claimed.
- the circadian clock generates a 24-hour rhythm through which physiology and behavior are adapted to daily changes in the environment.
- Many biological processes like hormone secretion, and sleep-wake cycles are controlled by the circadian clock. Therefore, an innate malfunctioning of the circadian clock and the related pathways can cause various pathologies. Sleep disorders, altered metabolism, obesity, diabetes, mood disorders, cancer, and cardiovascular diseases are all linked with abnormal circadian rhythm.
- BMAL1 and CLOCK are transcription factors that bind E-box elements (CACGTG) in clock-controlled genes including Period and Cryptochrome and thereby exert a positive effect on circadian transcription.
- the mammalian PERIOD (PER) and CRYPTOCHROME (CRY) proteins form heterodimers that interact with casein kinase Is (CKIs) and then translocate into nucleus where CRY acts as a negative regulator of BMALl/CLOCK-driven transcription.
- CKIs casein kinase Is
- FBXL3 and FBXL21 and directed to proteasome for the degradation.
- FBXL21 and FBXL3 act antagonistically on CRY to regulate its stability differentially in the cytosol and nucleus, respectively.
- the FBXL3 protein participates in the negative feedback loop by binding to the CRYl and CRY2 proteins to facilitate their polyubiquitination and their subsequent degradation by the proteasome [1, 2]
- retinoic acid receptor-related orphan receptors RORs
- REV-ERBs which control the transcription of the Bmall gene and, in turn, regulate molecular clock
- structure-based drug design approach can be utilized to design small molecules by using the available crystal structure core clock proteins [13, 14] .
- the crystal structure of the CRY -FBXL3 revealed the critical region (FAD binding pocket) on CRY for the FBXL3 interaction [14]
- circadian rhythm controlling molecules and compositions as potential treatments for clock-related diseases, including diabetes. It has therefore become increasingly interesting to identify small molecules that can specifically modulate regulatory core clock proteins since they have the potential to manage these diseases.
- Cryptochrome 1 and 2 (Cryl and 2), one of the key circadian clock genes, plays an important role in circadian clock and clock-related diseases.
- CRYs are associated with diabetes and may act as a novel switch in hepatic fuel metabolism by limiting glucose production [19, 20]
- CRYs may be a prognostic biomarker and a promising therapeutic target for treatment of diabetes.
- advances in drug discovery directed to identifying therapeutic small molecules for CRY binding there is still a scarcity of compounds that are potent, efficacious, and selective stabilizer of cryptochromes.
- there is a scarcity of compounds effective in the treatment and/or prevention of disorders associated with the circadian rhythm are satisfied by the present invention.
- a CRY-binding compound of Formula I or pharmaceutically acceptable salts thereof Accordingly, a broad embodiment of the invention is directed to a CRY -binding compound of Formula I:
- the other aspect of the present invention is to provide a CRY -binding compound for treating and/or preventing a circadian rhythm associated diseases or disorders, including diabetes, wherein the compound is characterized by stabilizing of Cryptochromes (CRY s).
- CRY s Cryptochromes
- the present invention relates to a CRY-binding compound of the invention for use in increasing the stability of CRY 1/2 in a mammal.
- Another aspect of the present invention is to provide a CRY -binding compound capable of controlling circadian rhythm via lengthening the period length.
- Another embodiment of the present invention relates to a method for identifying a compound for stabilizing the CRY proteins.
- a further aspect relates to a process for the synthesis of the CRY-binding compound.
- the invention can be used for the preparation of a medicament useful in the treatment and/or prevention of disorders by means of the stabilization of cryptochromes.
- Yet another objective of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- FIG. 1 is an illustration of FORMULA I increases the half-life of CRY1 and 2.
- FORMULA I increased the degradation rate of Cryl-dLuc and Cry2-dLuc dose dependently.
- HEK 293T cells were transfected with Cryl-dLucand Cry2-Luc plasmids.
- 24h after transfection cells were treated with different doses of FORMULA I or solvent (DMSO final 0.5%) as control.
- FIG. 2 is an illustration of bioluminescence rhythms of U20S Bmal-dLuc cells treated with various doses of FORMULA I.
- Figure 3 is an illustration of bioluminescence rhythms of NIH3T3 mPerl-dLuc cells treated with various doses of FORMULA I.
- Figure 4 is an illustration of western blot analysis of unsynchronized U20S cells treated with FORMULA I.
- Figure 5 is an illustration of RT-qPCR analysis of unsynchronized U20S cells treated with FORMULA I. mRNA levels of Cryl, Cry2, Per2, Dbp, Rev-erba, Rora, Clock, and Bmall relative to RplpO. Data are given as mean ⁇ SEM from at least 3 individual experiments. Statistical analysis performed using one-way ANOVA (*p ⁇ 0.05, **p ⁇ 0.01, ns: non-significant).
- Figure 6 is an illustration of dose-dependent effects of FORMULA I on CRYl- DLUCand CRY1-W399L-LUC mutant half-life relative to DMSO. Data are given as mean ⁇ SEM from at least 3 individual experiments. Statistical analysis performed using one-way ANOVA (**p ⁇ 0.01, ns: non-significant).
- Figure 7 is an illustration of effect of FORMULA I on gluconeogenesis in HepG2 cells.
- Statistical analysis performed using one-way ANOVA (*p ⁇ 0.05, ***p ⁇ 0.001).
- Figure 8 is an illustration of synthesis of Formula 1.
- CRY-binding small compound In the present invention, it is aimed to discover a novel CRY-binding small compound using a structure-based approach by targeting the FAD binding pocket which is critical for the FBXL3 interaction.
- the CRY-binding compound was identified that stabilizes cryptochromes (CRYs; CRYl/2; CRYl and CRY2) and decrease the degradation of CRYs in vitro.
- the stability of CRY proteins is important because they can alter the period and amplitude of the circadian rhythm, in turn, affecting metabolism.
- the CRY-binding compound caused the repression of gluconeogenic genes Phosphoenolpyruvate carboxykinase 1 ( Pckl ) and Glucose 6 phosphatase (' G6pc ) and lowered the glucose production during glucagon-induced gluconeogenesis.
- Pckl carboxykinase 1
- Glucose 6 phosphatase ' G6pc
- the present invention relates to a CRY-binding compound (Formula I).
- Form I or “compound” or “FORMULA I” refers to compounds of Formula I, prodrugs thereof, salts of the compound and/or prodrug, hydrates or solvates of the compound, stereoisomers, tautomers, isotopically labeled compounds, and polymorphs.
- the present invention relates to a CRY-binding compound, capable of stabilizing CRYl and CRY2 proteins.
- the invention relates to a compound having the following Formula I: or a pharmaceutically acceptable salt thereof.
- the present invention is represented by the compound of Formula I for use as a medicament.
- the invention relates to said compound of Formula I for use of treating and/or preventing a circadian rhythm associated diseases or disorders, including diabetes, wherein the compound is characterized by stabilizing of Cryptochromes (CRYs; CRY 1 and CRY 2).
- the invention relates to said compound of Formula I for use as a CRY protein stabilizer, for the treatment of type 2 diabetes mellitus.
- the present invention relates to a compound (Formula I) that binds to a CRYs and positively modulates CRY activity.
- the present invention relates to a novel CRY-binding small molecule that inhibits the degradation of CRYl and CRY2 proteins in the nucleus through the stabilization of the CRYl and CRY2 and thus increases CRYl/2 protein levels significantly in a dose dependent manner.
- Formula I When Formula I is present, it interacts with CRYs by binding to FAD binding pocket which is the pocket critical for the FBXL3 interaction and the degradation of CRYs by proteasome.
- Formula I forms p-p interactions with two residues W399 (W417 in CRY2) and W292 (W310 in CRY2). These residues are found in the FAD binding pocket where FBXLs bind for the ubiquitination of CRY. Docking results suggest that W399 amino acid residue in the CRYl and W417 amino acid residue in the CRY2 contribute to stable binding with energy of -10.1 kcal/mol.
- Formula I Upon binding of Formula I to CRY proteins, this interaction reduces the ubiquitination of CRY by FBXL3 and its proteasomal degradation, hence FORMULA I stabilizes the CRY proteins.
- Formula I exhibits period-lengthening activities by binding to the FAD-biding pocket of CRYl and CRY2 in competition with FBXL3.
- the compound directly targets the clock proteins, CRYl and CRY2, and lengthens the period of the circadian rhythm in human cell lines.
- period shortening molecules were previously disclosed as CRY destabilizers, GO044, GO200, and G0211 shortened the period while enhancing the CRY stability [15] .
- the compound affects period lengthening and amplitude reduction while enhancing the CRY stability.
- the disclosed compound exhibits selectivity and high affinity for the CRYl and CRY2 proteins.
- the interaction is potent.
- the affinity ranges from -9 to -13.5 kcal/mol, more preferably from -10 to -11 kcal/mol.
- a therapeutically effective amount of a compound of the present invention refers to a non-toxic and sufficient amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of the protein activity or protein: protein interaction, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease or disorder, etc.
- All of the various embodiments of the present invention as disclosed herein relate to methods of treating and/or preventing various diseases and disorders as described herein.
- the compound used in the method of this invention is capable of stabilizing CRYl and CRY2 proteins. It is known that cryptochromes also affect human health, including diabetes, sleep disorders, and many physiological disorders.
- the invention further provides methods for the treatment or prevention of circadian rhythm related disorders and diseases.
- circadian rhythm disorders include aging, sleep disorders, altered metabolism (metabolic syndromes), obesity, diabetes, mood disorders, cancer and cardiovascular diseases.
- Mood disorders including major depressive disorder, bipolar I disorder; sleep disorders including circadian rhythm sleep disorders such as shift work sleep disorder, jet lag syndrome, advanced sleep phase syndrome, non-24-hour sleep-wake syndrome, irregular sleep-wake rhythm and delayed sleep phase syndrome.
- the circadian rhythm related disease is diabetes, more preferably type 2 diabetes mellitus.
- glucagon-mediated expression of gluconeogenic genes Pckl and G6pc reduce when CRY 1/2 is either adenovirally overexpressed in mice [16] or stabilized by a small molecule in mouse hepatic cells [5] Moreover, glucose levels were also reduced in these studies.
- qPCR and glucose production assay were performed to test whether the stabilization of CRYl/2 by FORMULA I also represses the glucagon- mediated gluconeogenesis. It is found that the gluconeogenic genes Pckl and G6pc were repressed significantly in a dose dependent manner when Formula I treated cells were induced with glucagon.
- Formula I represses glucagon-induced gluconeogenesis in HepG2 cells by stabilizing CRY and hence reducing GPCR (G-protein-coupled receptor)-mediated cAMP levels.
- the compound as CRYs stabilizer is also glucagon-mediated gluconeogenesis repressor.
- the compound is used as novel therapeutic agent for diabetes, especially for the treatment of type 2 diabetes mellitus.
- the invention can be used for the preparation of a medicament for treatment and/or prevention of diseases or disorders associated with the circadian rhythm by means of the stabilization of cryptochromes.
- Yet another embodiment of the present invention is a compound defined above for the preparation of a medicament.
- the invention relates to a pharmaceutical composition comprising such compounds, uses and methods of use for such compounds in the treatment and/or prevention of disorders associated with the circadian rhythm.
- a pharmaceutical composition comprising the compound is useful in the treatment and/or prevention of circadian rhythm related diseases and disorders due the stabilization of CRY1 and CRY2.
- said pharmaceutical composition is for use as a medicament.
- the present invention relates to pharmaceutical compositions comprising at least one pharmaceutical carrier and a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- the present invention also relates to pharmaceutical compositions to treat and/or prevent a CRYl/2 -mediated disorders and/or diseases, such as diabetes related to the circadian rhythm.
- Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients or carriers suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practices.
- the disclosure relates to a method for the manufacture of a medicament for stabilizing CRY 1/2 in a mammal comprising combining a therapeutically effective amount of a disclosed compound with a pharmaceutically acceptable carrier or diluent.
- the present invention provides a method for identifying a compound for stabilizing CRYl/2.
- the method can be established using systems for pharmaceutical screening that are well known in the art.
- the present invention provides a method for identifying a compound that stabilize CRYl/2, wherein the method comprises contacting a compound with CRYl/2 proteins under conditions allowing for the interaction and determining whether the compound leads to increase in CRYl/2 level by using a system that uses a signal and/or a marker generated by the interaction between the compound and CRYl/2 to detect presence or absence or change of the signal and/or the marker.
- signal refers to a substance that can be detected directly by itself based on the physical properties or chemical properties thereof.
- FORMULA I increases the stability of CRYl/2 and lengthening the period of circadian rhythm in Bmall-dLuc U20S cells.
- Formula I caused the repression of gluconeogenic genes Pckl and G6pc, and lowered the glucose production during glucagon-induced gluconeogenesis in hepatic HepG2 cells.
- mice CRY1 (mCRYl) (PDB ID: 4K0R) and mouse CRY2 (mCRY2) (PDB ID: 4I6G) structures were obtained from protein databank.
- NAMD v. 2.6
- VMD v. 1.9.1
- program packages each protein was solvated in a rectangular box with TIP3P water molecules and neutralized with counter ions. Then the system was minimized and heated up to physiological temperature with 10K increments by running lOps simulation at each temperature.
- CHARMM-PARAM22 force field was used for the molecular dynamics (MD) simulations. After the equilibration of the system, MD simulation was run at 310 ° K for desired time. Pressure was controlled by Langevin piston method during the simulations.
- Time step was set to 2fs and the bonded interactions, the van der Waals interactions (12 ⁇ cutoff), long-range electrostatic interactions with particle-mesh Ewald (PME) were included for calculating the total force acting on the system.
- Last frame of the simulation was used as the “receptor” for the docking simulations.
- RMSD calculations were done using VMD RMSD utilities.
- Backbone atoms (C, CA, and N) of each residue were used for RMSD calculation by excluding their translational motions.
- the last frame of the simulation was utilized as the receptor for the docking analysis.
- Molecules were filtered according to the following criteria to eliminate non-relevant molecules: molecules should have less than 7 El- bond donor, less than 12 H-bond acceptor, less than 600 Da molecular weight, logP ⁇ 7, less than 8 rotatable bonds, at least 3 aromatic rings, and at least 4 rings.
- Openbabel, Autodock4.2, Autodock Tools4 [17] and Autodock [18] program packages which are free for academic purposes, were utilized to prepare ligands (small molecules) for the docking. Finally, more than 1 million compounds were docked to target pockets by using the Autodock Vina program.
- Target pocket for FAD and FBXL3 binding site was determined based on the CRY -FBXL3 crystal structure [14] Autodock Tools4 or PyMol (http://pymol.sourceforge.net/) software were used to visualize the docking results and protein structure, respectively.
- HEK293T, U20S, NIH3T3 and HepG2 cell lines were used for different experiments.
- the cells were maintained in Dulbecco’s modified Eagle’s Medium (DMEM, Gibco) supplemented with 10% heat-inactivated FBS (Gibco), 100 pg/ml streptomycin and 100 pg/ml penicillin (Gibco).
- DMEM Dulbecco modified Eagle’s Medium
- FBS heat-inactivated FBS
- streptomycin 100 pg/ml streptomycin
- 100 pg/ml penicillin Gibco
- the cell cultures were grown in an 85% humidified incubator at 37°C with 5% C02. To subculture the cells when they reach confluency, first the medium was removed, and the cells were washed with 5mL PBS (137 mM NaCl, 2.7 mM KC1, 10 mM Na2HP04, 1.8 mM KH2P04, pH 7.4).
- This assay was performed with two different equipments: Synergy HI (BioTek) with 96-well plate and LumiCycle luminometer (Actimetrics) with 35mm plates. Initial screening of molecules to determine their effect on the circadian period was performed in 96-well plate via Synergy HI. Clear 35-mm plates are used in LumiCycle luminometer which provides high resolution data describing the circadian oscillation. For 96-plate tests, 50000 U2-OS Bmall-dLuc cells were seeded on an opaque 96-well plate and cultured overnight. Next day cells were reset by adding dexamethasone (DXM) (0.1 mM final) for 2h.
- DXM dexamethasone
- bioluminescence recording media which contains the following in 1L: DMEM powder (sigma D-2902, 10X 1L), 0.35gr sodium bi-carbonate (tissue culture grade, sigma S5761), 3.5gr D(+) glucose powder (tissue culture grade, sigma G7021), lOmL 1M HEPES buffer (Gibco 15140-122), 2.5 mL Pen/Strep (lOOug/ml), 50mL 5% FBS and up to 1L sterile milliQ water. Luciferin is added freshly with O.lmM final concentration. Molecules were added to the bioluminescence recording media at desired concentration (0.5% final DMSO concentration).
- Luminescence values were recorded at 320C for each 30 minutes with 15 seconds integration time via Synergy HI luminometer for a week.
- LumiCycle 400x103 U2-OS Bmall-dLuc or NIH3T3 mPer2-dLuc cells were seeded to 35mm plates and then procedure given above was followed with a change in the last step. Plates were sealed with vacuum grease and placed to LumiCycle. Each plate was recorded continuously every 10 minutes for 70 seconds at 370C via photomultiplier tubes. Period and amplitude data were obtained from LumiCycle Analysis software.
- Cryl-/-/Cry2-/- mouse embryonic fibroblasts (CRYDKO MEFs) transiently transfected with pGL3-Per2-Luc (luciferase reporter) were used.
- 3x105 CRYDKO cells were seeded in 35mm clear plates.
- cells were transfected with 4000ng pGL3- Per2-Luc via Fugene6 transfection reagent according to the manufacturer’s instruction.
- 3 1 ratio of Fugene6 in m ⁇ against transfected DNA amount in pg was kept in transfections.
- 72h after transfection cells were synchronized with DXM for two hours. Then, medium was changed with lumicycle medium having DMSO or molecule, sealed with vacuum grease, and placed to LumiCycle.
- U20S cells were seeded on 35mm plates with a density of 3.5x105 cells/plate and incubated at 37°C with 5% C02. After 24 hours, small molecules (final 0.4% DMSO) were added at various doses. The cells were incubated for another 24 hours, and then washed and harvested with ice-cold PBS using a cell scraper (Nest Scientific). Harvested cells were centrifuged at 3000 x g, 4°C for 7 minutes and then supernatant was removed.
- RIPA buffer 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40, 0.5% SDS
- PMSF phenylmethylsulfonyl fluoride
- PIC IX Protease Inhibitor Cocktail
- the protein samples were mixed with 16.7pL 4X Laemmli Buffer (0.1% bromophenol blue, 8% SDS, 400 mM b-mercaptoethanol, 40% glycerol). Then, the samples were incubated in 95°C for 10 minutes and finally put on ice. For quantification of proteins, the proteins were separated according to their molecular weight using SDS-PAGE gel electrophoresis and then detected by Western blotting with corresponding antibodies. The samples were loaded to 10% SDS-PAGE gel.
- the proteins in the gel were transferred to polyvinylidene difluoride membrane (0.45 pm pore size Hydrophobic PVDF Transfer Membrane, Merck-Millipore) by electrophoresis.
- the membranes were blocked by incubation with 5% fat free milk powder in TBS-0.015% Tween 20 solution for 1 hour with gentle shaking at room temperature. Following this step, the membranes were incubated with primary antibody for 18 hours with gentle shaking at 4°C and consecutively incubated with secondary antibody for 1 hour with gentle shaking at room temperature.
- the primary antibodies used for detection of proteins are: Anti- CRY1 (Bethyl), Anti-CRY2 (Bethyl), Anti-PER2 (Bethyl), and Ah ⁇ -b-ACTIN (Cell Signaling).
- Anti-rabbit-HRP antibody (Cell Signaling) was used for CRY1, CRY2, and PER2 as the secondary antibody.
- Anti-mouse-HRP antibody (SantaCruz) was used for b-ACTIN as the secondary antibody.
- ECL Enhanced Chemiluminescence
- HRP substrate Advanced Chemiluminescence
- U20S cell line whereas, for genes involved in gluconeogenesis we used HepG2 cell line.
- U20S cells were harvested using the methodology described in Section 3.5. HepG2 cells were treated and harvested as described in Section 3.8.
- Total RNA isolation from the samples was performed with the NucleoSpin RNA kit (Macherey-Nagel) including DNase treatment. RNA is eluted with 50 pL DNase RNase free water. Using NanoDrop 2000 (Thermo Scientific) the approximate concentration and purity of RNA was measured. The integrity of the eluted RNA was confirmed by agarose gel electrophoresis where 1% agarose gel in prepared using DEPC (diethylpyrocarbonate) treated water.
- DEPC diethylpyrocarbonate
- First step of cDNA synthesis is denaturation and annealing of template RNA and oligo(dT)23VN (New England Biolabs). For this purpose, a mixture of 500 ng of RNA, 2 pL of oligo(dT)23, 1 pL of 10 mM dNTP mix was completed to 10 pL with DNase RNase free water. The mixture was incubated at 65 °C for 5 minutes and consecutively placed on ice (+4°C).
- the second step is the extension of cDNA where 2 pL from 10X M-MuLV buffer (New England Biolabs), 1 pL from M-MuLV Reverse Transcriptase (200 U/pL), 0.2 pL from RNase Inhibitor (40 U/mI) and 6.8 pL DNase RNase free water were added into the RNA-oligo(dT) mixture in the tube. The samples were kept at 42°C for 1 hour for extension reaction and then at 65 °C for 20 minutes for inactivation of the enzyme. Produced cDNA samples were diluted 1:5 with DNase and RNase free water for storage at - 20°C and serially diluted 1:25 to be used in quantitative PCR reactions.
- the cycling protocol is 8 seconds at 95°C (denaturation), 10 seconds at 60°C (annealing), 20 seconds at 72°C (elongation) using CFX Connect Real-Time PCR detection system (Bio-Rad).
- the product of qPCR was also analyzed by melt curve (Tm) and agarose gel imaging for checking the quality.
- the effect of small molecules on glucagon-induced gluconeogenesis was determined by comparing the expression of gluconeogenic genes using RT-qPCR and the glucose levels performing glucose production assay.
- HepG2 cells were seeded on 12-well plates with a density of 2x 105 cells/well in low glucose (1000 mg/L) DMEM with 10% FBS, 100 pg/ml streptomycin and 100 pg/ml penicillin.
- the medium was supplemented with 2 pg/ml insulin and lOOnM dexamethasone. Cells were incubated for 3 hours, then the medium was exchanged with low glucose DMEM without FBS. Subsequently, the small molecules (final 0.4% DMSO) were added at desired concentrations.
- the cells were treated with lOnM glucagon.
- Cells used in RT-qPCR analysis were harvested after 2 hours with ice-cold PBS using a cell scraper. After 3 hours, the cells used in glucose production assay were washed with warm glucose-free Krebs-Ringer bicarbonate buffer (118.5 mM NaCl, 4.74 mM KC1, 23.4 mM NaHC03, 1.18 mM KH2P04, 1.18 mM MgS02, 2.5 mM CaC12, and 25 mM HEPES - pH 7.6) containing 1% BSA, 100 qg/ml penicillin, 100 qg/ml streptomycin, and 0.29 mg/ml L-glutamine.
- warm glucose-free Krebs-Ringer bicarbonate buffer 118.5 mM NaCl, 4.74 mM KC1, 23.4 mM NaHC03, 1.18 mM KH2P04, 1.18 mM MgS02, 2.5 mM CaC12
- the cells were incubated in this buffer additionally containing 2 mM sodium pyruvate 20 mM sodium lactate for 4 hours. After the collection of the buffer, the glucose levels were measured using Glucose and Sucrose Assay Kit (Sigma, MAK013).
- Example 10 Statistical Analysis All statistical analysis was performed using GraphPad Prism 5 software. In the comparison of a single dose of the small molecule with control (DMSO), Student’s t-test was employed to calculate significance (p-value). For dose- dependent experiments, as a group all doses were compared, and p-value was calculated by employing one-way ANOVA (analysis of variance) followed by Dunnett's multiple comparisons test. Dunnett's multiple comparisons test compares each dose with the control (DMSO) separately in a pair-wise manner.
- DMSO control
- CRY and FBXL3/21 interaction sites for the identification of small molecules stabilizing CRYs.
- Small molecules with highest binding energies were identified by molecular docking studies on the CRY 1/2 and FBXL3/21 interaction sites.
- the mouse CRY1 (mCRYl) structure (PDB ID: 4K0R) was subjected to molecular simulation was performed on CRY1 to bring the structure near their physiological conditions as follow: After structure of CRY1 was solvated in a rectangular box and neutralized with counter ions, the system was minimized, heated up to physiological temperature (310°K) and simulated for 10ns.
- Root mean square deviation (RMSD) of backbone atoms showed convergence after initial increase upon minimization.
- the last frame of the simulation was utilized as the receptor for the docking analysis.
- Commercially available small molecule libraries with non-identified function were used as ligands.
- AutoDock Vina was used to screen approximately 2 million commercially available small molecules filtered by “Lipinski’s Rule of Five”. A final number of 32 compounds with affinities ranging from -9 to -13.5 kcal/mol were then tested experimentally.
- the toxicity of these top 32 molecules were evaluated on cells prior to in vitro screening using U2-OS cells by MTT at the dose of 20 mM.
- the small molecule doses yielding more than 90% cell viability were selected for further characterization.
- the 20 molecules were identified to be nontoxic at given concentration and selected for further characterization.
- TW68 The effect of the TW68 on CRY1 and CRY2 half-life was assessed using CRY1- dLuc and CRY2-dLuc as dose dependent manner.
- Plasmids contains Cryl and Cry2 genes fused with destabilized Luciferase genes, were transfected to HEK 293T cells. The cells treated with TW68 and cycloheximide inhibit protein synthesis. The samples were incubated for 16 hours in Synergy to be able to calculate half-life of luciferases based on bioluminance decay. Analysis of the results indicated that TW68 increased the half-life of CRYs in dose dependent manner.
- TW68 The effect of the TW68 on circadian clock was further investigated using U2-OS and NIH 3T3 cells stably expressing dLuc reporter, under the Bmall and Per2 promoters, respectively. Cells treated with TW68 had longer periods compared to control. TW68 lengthens period about 3 hours in U2-OS and about 2.6 hours in NIH 3T3 cells. Further analysis of amplitude in both cell lines in the presence of the TW68 revealed that the molecules also reduced the amplitude.
- TW68 The effect TW68 on transcription of clock output genes using U2-OS cells.
- U20S cells were treated with TW68 and DMSO and levels of clock genes transcripts were determined by RT-qPCR.
- the mRNA levels measured genes were normalized with respect to RplpO gene expression because its expression level is independent from circadian genes.
- TW68 treatment resulted in significant decrease of Cryl, Cry2, Per2, Dbp and Rev-erba expression in a dose-dependent manner.
- TW68 treatment there was no significant effect of TW68 treatment on Bmall and Clock expression.
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to ((1S,9S)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl}-7,11-diazatricyclo[7.3.1.0~2,7~] trideca-2,4-dien-6-one) compound and related derivatives. The compound of the invention is a CRY1/2-binding small molecule and also a stabilizer of CRY1 and CRY2 proteins, and is therefore useful, as pharmaceutical agent, especially in the treatment and/or prevention of disorders associated with the circadian rhythm, including CRY1-mediated diseases such as diabetes.
Description
((lS,9S)-ll-{[4-(l,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl} -7,ll-diazatricyclo[7.3.1.0~2,7~]trideca-2,4-dien-6-one) as a stabilizer of CRYs for the treatment of circadian rhythm associated diseases and disorders
FIELD OF THE INVENTION
The present invention discloses and claims ((lS,9S)-l l-{[4-(l,3-benzodioxol-5- ylamino)-8-methyl-2-quinazolinyl]methyl}-7, 1 l-diazatricyclo[7.3.1.0-2.7~| trideca-2,4-dien-6-one) (Formula I) as CRY-binding small compound and stabilizer of CRY s, and a method of using said compound Formula I for treating circadian rhythm associated diseases, including diabetes. Pharmaceutical compositions comprising Formula I and methods for the preparation of Formula I are also disclosed and claimed.
BACKGROUND
The circadian clock generates a 24-hour rhythm through which physiology and behavior are adapted to daily changes in the environment. Many biological processes like hormone secretion, and sleep-wake cycles are controlled by the circadian clock. Therefore, an innate malfunctioning of the circadian clock and the related pathways can cause various pathologies. Sleep disorders, altered metabolism, obesity, diabetes, mood disorders, cancer, and cardiovascular diseases are all linked with abnormal circadian rhythm.
At the molecular level, the clockwork of the cell involves several proteins that participate in positive and negative transcriptional/translational feedback loops (TTFL). BMAL1 and CLOCK are transcription factors that bind E-box elements
(CACGTG) in clock-controlled genes including Period and Cryptochrome and thereby exert a positive effect on circadian transcription. The mammalian PERIOD (PER) and CRYPTOCHROME (CRY) proteins form heterodimers that interact with casein kinase Is (CKIs) and then translocate into nucleus where CRY acts as a negative regulator of BMALl/CLOCK-driven transcription. Upon phosphorylation CRYs are ubiquitinated by E3 ubiquitin ligases e.g. FBXL3 and FBXL21 and directed to proteasome for the degradation. FBXL21 and FBXL3 act antagonistically on CRY to regulate its stability differentially in the cytosol and nucleus, respectively. The FBXL3 protein participates in the negative feedback loop by binding to the CRYl and CRY2 proteins to facilitate their polyubiquitination and their subsequent degradation by the proteasome [1, 2]
In addition there is a second feedback loop consists of retinoic acid receptor- related orphan receptors (RORs) and REV-ERBs which control the transcription of the Bmall gene and, in turn, regulate molecular clock [3]
Since the circadian system regulates several aspects of our physiology, it is not surprising that disturbed circadian rhythm can lead into diseases in human. It is, therefore, essential to find small molecules to correct disturbed circadian rhythm. There are several studies have been carried out to find small molecules affect circadian rhythm based on phenotypic changes in the circadian rhythm of reporter cells using high-throughput screening assay. These studies result in identification several molecules affect different features of circadian rhythm [4, 5, 6, 7] For example a molecule (named as GSK4112) was shown to enhance REV-ERB's repressor function toward Bmall transcription and greatly altered circadian clock and metabolism [8] Another example, identification of KL001 molecule, increases stability of the CRYs and suppresses the gluconeogenesis [5]
It has been shown that disturbed circadian rhythm can lead to various diseases including sleep disorders, glucose metabolism disorders, cardiovascular diseases,
and cancer. Therefore, it is essential to find small molecules to correct disturbed circadian rhythm. In recent years, many studies focused on the discovery of small molecules interacting with circadian clock proteins for the treatment of these diseases. These studies result in identification several molecules affect different features of circadian rhythm [9, 10, 11, 12] For example, identification of KL001 molecule, increases stability of the CRYs and suppresses the gluconeogenesis.
Alternatively, structure-based drug design approach can be utilized to design small molecules by using the available crystal structure core clock proteins [13, 14] . The crystal structure of the CRY -FBXL3 revealed the critical region (FAD binding pocket) on CRY for the FBXL3 interaction [14]
An effective method to identify small molecules that perturb a biological system is structure-based design. Since the crystal structures of clock proteins are now available, this approach can lead to identification of clock modulating compounds targeting clock proteins.
In the European patent document EP2408906A1, the role of AMPK in circadian rhythms and methods of screening for small molecules that modulate such rhythms are disclosed. The disclosure demonstrates that AMPK phosphorylates the transcription repressor CRY1 and CRY2 and stimulates their proteasomal degradation. According to this invention, the use of an AMP kinase agonist or antagonist is disclosed for the manufacture of a medicament to modulate circadian rhythms in a subject.
Many physiological variables require a robust circadian clock for their proper function. There is a need for circadian rhythm controlling molecules and compositions as potential treatments for clock-related diseases, including diabetes. It has therefore become increasingly interesting to identify small molecules that
can specifically modulate regulatory core clock proteins since they have the potential to manage these diseases.
Cryptochrome 1 and 2 (Cryl and 2), one of the key circadian clock genes, plays an important role in circadian clock and clock-related diseases. Recent studies suggested that CRYs are associated with diabetes and may act as a novel switch in hepatic fuel metabolism by limiting glucose production [19, 20] CRYs may be a prognostic biomarker and a promising therapeutic target for treatment of diabetes. Despite advances in drug discovery directed to identifying therapeutic small molecules for CRY binding, there is still a scarcity of compounds that are potent, efficacious, and selective stabilizer of cryptochromes. Furthermore, there is a scarcity of compounds effective in the treatment and/or prevention of disorders associated with the circadian rhythm. These needs and other needs are satisfied by the present invention.
SUMMARY OF THE INVENTION
According to a first aspect of the invention there is provided a CRY-binding compound of Formula I or pharmaceutically acceptable salts thereof. Accordingly, a broad embodiment of the invention is directed to a CRY -binding compound of Formula I:
The other aspect of the present invention is to provide a CRY -binding compound for treating and/or preventing a circadian rhythm associated diseases or disorders, including diabetes, wherein the compound is characterized by stabilizing of Cryptochromes (CRY s).
In a further aspect, the present invention relates to a CRY-binding compound of the invention for use in increasing the stability of CRY 1/2 in a mammal.
Another aspect of the present invention is to provide a CRY -binding compound capable of controlling circadian rhythm via lengthening the period length. Another embodiment of the present invention relates to a method for identifying a compound for stabilizing the CRY proteins.
A further aspect relates to a process for the synthesis of the CRY-binding compound.
The invention can be used for the preparation of a medicament useful in the treatment and/or prevention of disorders by means of the stabilization of cryptochromes.
Yet another objective of the present invention is to provide a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective
amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
This object and other objects of this invention become apparent from the detailed discussion of the invention that follows. Brief Description of Figures
The present invention is illustrated in the accompanying figures wherein;
Figure 1 is an illustration of FORMULA I increases the half-life of CRY1 and 2. FORMULA I increased the degradation rate of Cryl-dLuc and Cry2-dLuc dose dependently. HEK 293T cells were transfected with Cryl-dLucand Cry2-Luc plasmids. 24h after transfection cells were treated with different doses of FORMULA I or solvent (DMSO final 0.5%) as control. 24h after molecule treatment cells were treated with cycloheximide (20pg/ml final) and bioluminescence was recorded. Normalized half-life is shown with ± SEM (n=4 with triplicates). *p<0.05 **p<0.01, all others are non-significant). Figure 2 is an illustration of bioluminescence rhythms of U20S Bmal-dLuc cells treated with various doses of FORMULA I. A) Raw data recorded for 7 days. B) Dose-dependent effect of FORMULA I on period (hr) and amplitude (counts/s) of the oscillation. Data are given as mean ± SEM from at least 3 individual experiments. Statistical analysis performed using one-way ANOVA with Dunnett's multiple comparisons test (p*<0.05, **p<0.01, ***p<0.001, all others are non-significant).
Figure 3 is an illustration of bioluminescence rhythms of NIH3T3 mPerl-dLuc cells treated with various doses of FORMULA I.
Figure 4 is an illustration of western blot analysis of unsynchronized U20S cells treated with FORMULA I. A) CRY1, B) CRY2, and C) PER2 protein level
normalized with b-ACTIN. Data are given as mean ± SEM from at least 3 individual experiments. Statistical analysis performed using one-way ANOVA with Dunnetfs multiple comparisons test (*p<0.05, ***p<0.001, all others are non-significant).
Figure 5 is an illustration of RT-qPCR analysis of unsynchronized U20S cells treated with FORMULA I. mRNA levels of Cryl, Cry2, Per2, Dbp, Rev-erba, Rora, Clock, and Bmall relative to RplpO. Data are given as mean ± SEM from at least 3 individual experiments. Statistical analysis performed using one-way ANOVA (*p<0.05, **p<0.01, ns: non-significant).
Figure 6 is an illustration of dose-dependent effects of FORMULA I on CRYl- DLUCand CRY1-W399L-LUC mutant half-life relative to DMSO. Data are given as mean ± SEM from at least 3 individual experiments. Statistical analysis performed using one-way ANOVA (**p<0.01, ns: non-significant).
Figure 7 is an illustration of effect of FORMULA I on gluconeogenesis in HepG2 cells. A) RT-qPCR analysis of gluconeogenic Pckl and G6pc genes when cells were treated with FORMULA I and induced with glucagon. B) Glucose production amount of cells treated with FORMULA I and induced with glucagon. Statistical analysis performed using one-way ANOVA (*p<0.05, ***p<0.001).
Figure 8 is an illustration of synthesis of Formula 1.
DETAILED DESCRIPTION OF THE INVENTION
In the present invention, it is aimed to discover a novel CRY-binding small compound using a structure-based approach by targeting the FAD binding pocket which is critical for the FBXL3 interaction. As a result, the interaction of a CRY- binding compound with CRYl and CRY2 has been predicted in silico and then demonstrated experimentally.
The CRY-binding compound was identified that stabilizes cryptochromes (CRYs; CRYl/2; CRYl and CRY2) and decrease the degradation of CRYs in vitro. The stability of CRY proteins is important because they can alter the period and amplitude of the circadian rhythm, in turn, affecting metabolism.
Furthermore, it was discovered that, as a result of this interaction, the subsequent degradation of CRYs by proteasome is affected by the CRY-binding compound resulting blocking the proteasome-mediated degradation of CRYl and CRY2 thereof. The CRY-binding compound leads to increase in CRYl or CRY2 half- life. These results also lead to period lengthening and amplitude reduction.
Moreover, the CRY-binding compound caused the repression of gluconeogenic genes Phosphoenolpyruvate carboxykinase 1 ( Pckl ) and Glucose 6 phosphatase (' G6pc ) and lowered the glucose production during glucagon-induced gluconeogenesis. In previous studies, it was discovered that increase in CRY proteins levels inhibit glucagon-induced gluconeogenesis. These results show the therapeutic potential of the compound, a CRY stabilizer, for the treatment of type 2 diabetes mellitus. As used herein, the terms "treat", "treatment" and "treating" refer to therapeutic treatments includes the reduction or amelioration of the progression, severity and/or duration of a disease or disorder.
The present invention relates to a CRY-binding compound (Formula I).
Unless specified otherwise, the term "Formula I " or “compound” or “FORMULA I” refers to compounds of Formula I, prodrugs thereof, salts of the compound and/or prodrug, hydrates or solvates of the compound, stereoisomers, tautomers, isotopically labeled compounds, and polymorphs.
It is an object of this invention to provide a CRY -binding small compound having the chemical name ((lS,9S)-l l-{[4-(l,3-benzodioxol-5-ylamino)-8-methyl-2- quinazolinyl]methyl}-7,l l-diazatricyclo[7.3.1.0-2, 7~] trideca-2,4-dien-6-one) IUPAC) as stabilizer of CRY proteins. In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the present invention relates to a CRY-binding compound, capable of stabilizing CRYl and CRY2 proteins. In this regard, the invention relates to a compound having the following Formula I:
or a pharmaceutically acceptable salt thereof.
In a general context, the present invention is represented by the compound of Formula I for use as a medicament.
In yet another aspect, the invention relates to said compound of Formula I for use of treating and/or preventing a circadian rhythm associated diseases or disorders, including diabetes, wherein the compound is characterized by stabilizing of Cryptochromes (CRYs; CRY 1 and CRY 2).
Moreover, the invention relates to said compound of Formula I for use as a CRY protein stabilizer, for the treatment of type 2 diabetes mellitus.
In a further aspect, the present invention relates to a compound (Formula I) that binds to a CRYs and positively modulates CRY activity.
The present invention relates to a novel CRY-binding small molecule that inhibits the degradation of CRYl and CRY2 proteins in the nucleus through the stabilization of the CRYl and CRY2 and thus increases CRYl/2 protein levels significantly in a dose dependent manner.
When Formula I is present, it interacts with CRYs by binding to FAD binding pocket which is the pocket critical for the FBXL3 interaction and the degradation of CRYs by proteasome. Formula I forms p-p interactions with two residues W399 (W417 in CRY2) and W292 (W310 in CRY2). These residues are found in the FAD binding pocket where FBXLs bind for the ubiquitination of CRY. Docking results suggest that W399 amino acid residue in the CRYl and W417 amino acid residue in the CRY2 contribute to stable binding with energy of -10.1 kcal/mol. Upon binding of Formula I to CRY proteins, this interaction reduces the ubiquitination of CRY by FBXL3 and its proteasomal degradation, hence FORMULA I stabilizes the CRY proteins. Formula I exhibits period-lengthening activities by binding to the FAD-biding pocket of CRYl and CRY2 in competition with FBXL3. The compound directly targets the clock proteins, CRYl and CRY2, and lengthens the period of the circadian rhythm in human cell lines. Although period shortening molecules were previously disclosed as CRY destabilizers, GO044, GO200, and G0211 shortened the period while enhancing the CRY stability [15] .
In the present invention it is found that the compound affects period lengthening and amplitude reduction while enhancing the CRY stability.
In one embodiment of the invention, the disclosed compound exhibits selectivity and high affinity for the CRYl and CRY2 proteins. Thus, the interaction is potent.
In the present invention the affinity ranges from -9 to -13.5 kcal/mol, more preferably from -10 to -11 kcal/mol.
As used herein, the term "stabilize", "stabilization" or "stabilizing" refers to inhibition of degradation or increased half-life of CRY1 and CRY2 in the nucleus. The term "a therapeutically effective amount" of a compound of the present invention refers to a non-toxic and sufficient amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of the protein activity or protein: protein interaction, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease or disorder, etc.
All of the various embodiments of the present invention as disclosed herein relate to methods of treating and/or preventing various diseases and disorders as described herein. As stated herein the compound used in the method of this invention is capable of stabilizing CRYl and CRY2 proteins. It is known that cryptochromes also affect human health, including diabetes, sleep disorders, and many physiological disorders.
The invention further provides methods for the treatment or prevention of circadian rhythm related disorders and diseases. Non-limiting examples of circadian rhythm disorders include aging, sleep disorders, altered metabolism (metabolic syndromes), obesity, diabetes, mood disorders, cancer and cardiovascular diseases. Mood disorders including major depressive disorder, bipolar I disorder; sleep disorders including circadian rhythm sleep disorders such as shift work sleep disorder, jet lag syndrome, advanced sleep phase syndrome, non-24-hour sleep-wake syndrome, irregular sleep-wake rhythm and delayed sleep phase syndrome.
In a preferred embodiment of the invention, the circadian rhythm related disease is diabetes, more preferably type 2 diabetes mellitus.
Previous studies have revealed that glucagon-mediated expression of gluconeogenic genes Pckl and G6pc reduce when CRY 1/2 is either adenovirally overexpressed in mice [16] or stabilized by a small molecule in mouse hepatic cells [5] Moreover, glucose levels were also reduced in these studies. In the present invention qPCR and glucose production assay were performed to test whether the stabilization of CRYl/2 by FORMULA I also represses the glucagon- mediated gluconeogenesis. It is found that the gluconeogenic genes Pckl and G6pc were repressed significantly in a dose dependent manner when Formula I treated cells were induced with glucagon. In line with this observation, treatment of cells with Formula I resulted in significantly decreased glucose production in a dose dependent manner. Overall, Formula I represses glucagon-induced gluconeogenesis in HepG2 cells by stabilizing CRY and hence reducing GPCR (G-protein-coupled receptor)-mediated cAMP levels.
According to the invention, it is found that the compound as CRYs stabilizer is also glucagon-mediated gluconeogenesis repressor. In another embodiment of the invention, the compound is used as novel therapeutic agent for diabetes, especially for the treatment of type 2 diabetes mellitus. The invention can be used for the preparation of a medicament for treatment and/or prevention of diseases or disorders associated with the circadian rhythm by means of the stabilization of cryptochromes. Yet another embodiment of the present invention is a compound defined above for the preparation of a medicament. Moreover, the invention relates to a pharmaceutical composition comprising such compounds, uses and methods of use for such compounds in the treatment and/or prevention of disorders associated with the circadian rhythm. In other
embodiment of the present invention, a pharmaceutical composition comprising the compound is useful in the treatment and/or prevention of circadian rhythm related diseases and disorders due the stabilization of CRY1 and CRY2. In a further object, said pharmaceutical composition is for use as a medicament.
The present invention relates to pharmaceutical compositions comprising at least one pharmaceutical carrier and a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
The present invention also relates to pharmaceutical compositions to treat and/or prevent a CRYl/2 -mediated disorders and/or diseases, such as diabetes related to the circadian rhythm.
Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients or carriers suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practices.
In one aspect, the disclosure relates to a method for the manufacture of a medicament for stabilizing CRY 1/2 in a mammal comprising combining a therapeutically effective amount of a disclosed compound with a pharmaceutically acceptable carrier or diluent.
The present invention provides a method for identifying a compound for stabilizing CRYl/2. The method can be established using systems for pharmaceutical screening that are well known in the art.
In one aspect, the present invention provides a method for identifying a compound that stabilize CRYl/2, wherein the method comprises contacting a compound with CRYl/2 proteins under conditions allowing for the interaction and determining whether the compound leads to increase in CRYl/2 level by using a system that uses a signal and/or a marker generated by the interaction between the compound and CRYl/2 to detect presence or absence or change of the signal and/or the
marker. The term "signal" as used herein refers to a substance that can be detected directly by itself based on the physical properties or chemical properties thereof.
These examples are intended to representative of specific embodiments of the invention, and are not intended as limiting the scope of the invention. SPECIFIC EMBODIMENTS
In these embodiments, a structure-based design was applied to find small molecules that specifically bind to the CRY proteins. After identifying candidate molecules by virtual screening, experimental studies lead to discover a compound (Formula I, also mentioned as TW68 below) that specifically binds to CRYs. The compound, named hereafter FORMULA I, increases the stability of CRYl/2 and lengthening the period of circadian rhythm in Bmall-dLuc U20S cells. Moreover, Formula I caused the repression of gluconeogenic genes Pckl and G6pc, and lowered the glucose production during glucagon-induced gluconeogenesis in hepatic HepG2 cells. Examples
Example 1 In silico search for compounds that interact with CRY1 and CRY2
Molecular Dynamics Stimulation
The mouse CRY1 (mCRYl) (PDB ID: 4K0R) and mouse CRY2 (mCRY2) (PDB ID: 4I6G) structures were obtained from protein databank. For each structure, using the NAMD (v. 2.6) and VMD (v. 1.9.1) program packages each protein was solvated in a rectangular box with TIP3P water molecules and neutralized with counter ions. Then the system was minimized and heated up to physiological temperature with 10K increments by running lOps simulation at each temperature. CHARMM-PARAM22 force field was used for the molecular dynamics (MD)
simulations. After the equilibration of the system, MD simulation was run at 310°K for desired time. Pressure was controlled by Langevin piston method during the simulations. Time step was set to 2fs and the bonded interactions, the van der Waals interactions (12Ά cutoff), long-range electrostatic interactions with particle-mesh Ewald (PME) were included for calculating the total force acting on the system. Last frame of the simulation was used as the “receptor” for the docking simulations.
RMSD calculations were done using VMD RMSD utilities. Backbone atoms (C, CA, and N) of each residue were used for RMSD calculation by excluding their translational motions. The last frame of the simulation was utilized as the receptor for the docking analysis.
Docking Setup
More than 8 million small molecules with non-identified functions were used as ligands for the docking. Molecules were filtered according to the following criteria to eliminate non-relevant molecules: molecules should have less than 7 El- bond donor, less than 12 H-bond acceptor, less than 600 Da molecular weight, logP < 7, less than 8 rotatable bonds, at least 3 aromatic rings, and at least 4 rings. Openbabel, Autodock4.2, Autodock Tools4 [17] and Autodock [18] program packages which are free for academic purposes, were utilized to prepare ligands (small molecules) for the docking. Finally, more than 1 million compounds were docked to target pockets by using the Autodock Vina program. Target pocket for FAD and FBXL3 binding site was determined based on the CRY -FBXL3 crystal structure [14] Autodock Tools4 or PyMol (http://pymol.sourceforge.net/) software were used to visualize the docking results and protein structure, respectively.
Small molecules with highest binding energies were identified by molecular docking studies on the CRYl/2 and FBXL3 interaction site. Molecular docking
results of TW68 to CRY1 revealed several residues on FBXL3/21 binding site that interact with TW68. TW68 forms p-p interactions with two residues W399 (W417 in CRY2) and W292 (W310 in CRY2). These residues are found in the FAD binding pocket where FBXLs bind for the ubiquitination of CRY [14, 22;]. Docking results suggest that W399 amino acid residue in the CRYl and W417 amino acid residue in the CRY2 contribute to stable binding with energy of -10.1 kcal/mol. Replacing the amino acid residue to another amino acid should eliminate binding of the CRYs to TW68.
Example 3 Cell Culture
HEK293T, U20S, NIH3T3 and HepG2 cell lines were used for different experiments. The cells were maintained in Dulbecco’s modified Eagle’s Medium (DMEM, Gibco) supplemented with 10% heat-inactivated FBS (Gibco), 100 pg/ml streptomycin and 100 pg/ml penicillin (Gibco). The cell cultures were grown in an 85% humidified incubator at 37°C with 5% C02. To subculture the cells when they reach confluency, first the medium was removed, and the cells were washed with 5mL PBS (137 mM NaCl, 2.7 mM KC1, 10 mM Na2HP04, 1.8 mM KH2P04, pH 7.4). Then, cells were detached by adding lmL Trypsin/EDTA (0.25%:0.02%, PAN Biotech) and resuspended with 4 mL fresh medium. Finally, in a new 10cm plate (NEST Biotechnology), 1 mL of the resuspended cells were mixed with 9 mL fresh medium.
Example 4 Real-Time Bioluminescence Monitoring of Circadian Rhythm
This assay was performed with two different equipments: Synergy HI (BioTek) with 96-well plate and LumiCycle luminometer (Actimetrics) with 35mm plates. Initial screening of molecules to determine their effect on the circadian period was performed in 96-well plate via Synergy HI. Clear 35-mm plates are used in LumiCycle luminometer which provides high resolution data describing the
circadian oscillation. For 96-plate tests, 50000 U2-OS Bmall-dLuc cells were seeded on an opaque 96-well plate and cultured overnight. Next day cells were reset by adding dexamethasone (DXM) (0.1 mM final) for 2h. Then medium is changed to bioluminescence recording media which contains the following in 1L: DMEM powder (sigma D-2902, 10X 1L), 0.35gr sodium bi-carbonate (tissue culture grade, sigma S5761), 3.5gr D(+) glucose powder (tissue culture grade, sigma G7021), lOmL 1M HEPES buffer (Gibco 15140-122), 2.5 mL Pen/Strep (lOOug/ml), 50mL 5% FBS and up to 1L sterile milliQ water. Luciferin is added freshly with O.lmM final concentration. Molecules were added to the bioluminescence recording media at desired concentration (0.5% final DMSO concentration). Plates were sealed with optically clear film to prevent evaporation and gas exchange thereby to maintain homeostasis of the cells. Luminescence values were recorded at 320C for each 30 minutes with 15 seconds integration time via Synergy HI luminometer for a week.
For LumiCycle, 400x103 U2-OS Bmall-dLuc or NIH3T3 mPer2-dLuc cells were seeded to 35mm plates and then procedure given above was followed with a change in the last step. Plates were sealed with vacuum grease and placed to LumiCycle. Each plate was recorded continuously every 10 minutes for 70 seconds at 370C via photomultiplier tubes. Period and amplitude data were obtained from LumiCycle Analysis software.
To detect the effect of FORMULA I in the absence of CRYs, Cryl-/-/Cry2-/- mouse embryonic fibroblasts (CRYDKO MEFs) transiently transfected with pGL3-Per2-Luc (luciferase reporter) were used. 3x105 CRYDKO cells were seeded in 35mm clear plates. Next day, cells were transfected with 4000ng pGL3- Per2-Luc via Fugene6 transfection reagent according to the manufacturer’s instruction. In short, 3 : 1 ratio of Fugene6 in mΐ against transfected DNA amount in pg was kept in transfections. 72h after transfection cells were synchronized with
DXM for two hours. Then, medium was changed with lumicycle medium having DMSO or molecule, sealed with vacuum grease, and placed to LumiCycle.
Example 5 SDS-PAGE and Western Blotting
U20S cells were seeded on 35mm plates with a density of 3.5x105 cells/plate and incubated at 37°C with 5% C02. After 24 hours, small molecules (final 0.4% DMSO) were added at various doses. The cells were incubated for another 24 hours, and then washed and harvested with ice-cold PBS using a cell scraper (Nest Scientific). Harvested cells were centrifuged at 3000 x g, 4°C for 7 minutes and then supernatant was removed. For cell lysis, RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40, 0.5% SDS) is prepared with freshly added 1 mM phenylmethylsulfonyl fluoride (PMSF) and IX Protease Inhibitor Cocktail (PIC, Thermo Scientific). While keeping the cells on ice, 60 pL RIPA buffer was added to cell pellets and samples with buffer were pipetted up and down every 5 minutes for 20 minutes. Then, the lysed cells were centrifuged at 13,000 x g, 4°C for 15 minutes to eliminate cell debris. The supernatants were collected, and total protein concentration of the samples were measured using Pierce Protein Assay (Thermo Scientific). The protein samples were mixed with 16.7pL 4X Laemmli Buffer (0.1% bromophenol blue, 8% SDS, 400 mM b-mercaptoethanol, 40% glycerol). Then, the samples were incubated in 95°C for 10 minutes and finally put on ice. For quantification of proteins, the proteins were separated according to their molecular weight using SDS-PAGE gel electrophoresis and then detected by Western blotting with corresponding antibodies. The samples were loaded to 10% SDS-PAGE gel. After the gel was run at 100 mV for 90 minutes, the proteins in the gel were transferred to polyvinylidene difluoride membrane (0.45 pm pore size Hydrophobic PVDF Transfer Membrane, Merck-Millipore) by electrophoresis. The membranes were blocked by incubation with 5% fat free milk powder in TBS-0.015% Tween 20 solution for 1 hour with gentle shaking at room temperature. Following this step, the membranes were incubated with
primary antibody for 18 hours with gentle shaking at 4°C and consecutively incubated with secondary antibody for 1 hour with gentle shaking at room temperature. The primary antibodies used for detection of proteins are: Anti- CRY1 (Bethyl), Anti-CRY2 (Bethyl), Anti-PER2 (Bethyl), and Ahΐί-b-ACTIN (Cell Signaling). Anti-rabbit-HRP antibody (Cell Signaling) was used for CRY1, CRY2, and PER2 as the secondary antibody. Anti-mouse-HRP antibody (SantaCruz) was used for b-ACTIN as the secondary antibody. Finally, the proteins were visualized with ECL (Enhanced Chemiluminescence) HRP substrate (Advansta) using ChemiDoc Imaging System (Bio-Rad).
Example 6 RNA Isolation and cDNA Preparation
To investigate the effect of small molecules on expression levels of circadian genes, we utilized U20S cell line whereas, for genes involved in gluconeogenesis we used HepG2 cell line. U20S cells were harvested using the methodology described in Section 3.5. HepG2 cells were treated and harvested as described in Section 3.8. Total RNA isolation from the samples was performed with the NucleoSpin RNA kit (Macherey-Nagel) including DNase treatment. RNA is eluted with 50 pL DNase RNase free water. Using NanoDrop 2000 (Thermo Scientific) the approximate concentration and purity of RNA was measured. The integrity of the eluted RNA was confirmed by agarose gel electrophoresis where 1% agarose gel in prepared using DEPC (diethylpyrocarbonate) treated water.
First step of cDNA synthesis is denaturation and annealing of template RNA and oligo(dT)23VN (New England Biolabs). For this purpose, a mixture of 500 ng of RNA, 2 pL of oligo(dT)23, 1 pL of 10 mM dNTP mix was completed to 10 pL with DNase RNase free water. The mixture was incubated at 65 °C for 5 minutes and consecutively placed on ice (+4°C). The second step is the extension of cDNA where 2 pL from 10X M-MuLV buffer (New England Biolabs), 1 pL from M-MuLV Reverse Transcriptase (200 U/pL), 0.2 pL from RNase Inhibitor (40
U/mI) and 6.8 pL DNase RNase free water were added into the RNA-oligo(dT) mixture in the tube. The samples were kept at 42°C for 1 hour for extension reaction and then at 65 °C for 20 minutes for inactivation of the enzyme. Produced cDNA samples were diluted 1:5 with DNase and RNase free water for storage at - 20°C and serially diluted 1:25 to be used in quantitative PCR reactions.
Example 7 Real Time - Polymerase Chain Reaction (RT-PCR)
Real time - quantitative PCR method was implemented for detecting the effect of small molecules on expression levels of core clock genes and gluconeogenic genes. Primer sequences are listed in Appendix B. The reference gene used in this project was ribosomal protein, large, P0 (RplpO) [202] The reaction mixture consisted of 8 pL SYBR Green (Bioline), 8 pL DNase free water, 1 pL primer mixture (forward and reverse primers: lOpmol each), and 3 pL cDNA obtained as described in Section 3.6. After 4 minutes of polymerase activation at 95°C, the cycling protocol is 8 seconds at 95°C (denaturation), 10 seconds at 60°C (annealing), 20 seconds at 72°C (elongation) using CFX Connect Real-Time PCR detection system (Bio-Rad). The product of qPCR was also analyzed by melt curve (Tm) and agarose gel imaging for checking the quality.
Example 8 Gluconeogenesis Experiments
The effect of small molecules on glucagon-induced gluconeogenesis was determined by comparing the expression of gluconeogenic genes using RT-qPCR and the glucose levels performing glucose production assay. HepG2 cells were seeded on 12-well plates with a density of 2x 105 cells/well in low glucose (1000 mg/L) DMEM with 10% FBS, 100 pg/ml streptomycin and 100 pg/ml penicillin. The medium was supplemented with 2 pg/ml insulin and lOOnM dexamethasone. Cells were incubated for 3 hours, then the medium was exchanged with low glucose DMEM without FBS. Subsequently, the small molecules (final 0.4%
DMSO) were added at desired concentrations. After 18 hours, the cells were treated with lOnM glucagon. Cells used in RT-qPCR analysis were harvested after 2 hours with ice-cold PBS using a cell scraper. After 3 hours, the cells used in glucose production assay were washed with warm glucose-free Krebs-Ringer bicarbonate buffer (118.5 mM NaCl, 4.74 mM KC1, 23.4 mM NaHC03, 1.18 mM KH2P04, 1.18 mM MgS02, 2.5 mM CaC12, and 25 mM HEPES - pH 7.6) containing 1% BSA, 100 qg/ml penicillin, 100 qg/ml streptomycin, and 0.29 mg/ml L-glutamine. Then, the cells were incubated in this buffer additionally containing 2 mM sodium pyruvate 20 mM sodium lactate for 4 hours. After the collection of the buffer, the glucose levels were measured using Glucose and Sucrose Assay Kit (Sigma, MAK013).
Example 9 CRY-LUC Degradation Assay
40ng of Cry 1 -Luc, Cry2-Luc, mutant Cryl-dLucplasmids or 5ng Luc plasmid were reverse transfected to 4x104 HEK293T cells on opaque 96-well plate with flat bottom via PEI transfection reagent. 24h after transfection, cells were treated with molecules or solvent (DMSO). 24h of post molecule treatment cells were treated with luciferin (0.4mM final) and HEPES (lOmM final and pH=7.2). After 2h, cycloheximide (20qg/ml final) was added to wells to stop protein synthesis. Plate was sealed with optically clear film and placed to Synergy HE Luminescence readings were recorded every lOmin at 320C for 24 h. Half-life of protein was calculated via one-phase exponential decay fitting function in GraphPad Prism5 software. For each molecule or control at least three replicates were done in each experiment.
Example 10 Statistical Analysis
All statistical analysis was performed using GraphPad Prism 5 software. In the comparison of a single dose of the small molecule with control (DMSO), Student’s t-test was employed to calculate significance (p-value). For dose- dependent experiments, as a group all doses were compared, and p-value was calculated by employing one-way ANOVA (analysis of variance) followed by Dunnett's multiple comparisons test. Dunnett's multiple comparisons test compares each dose with the control (DMSO) separately in a pair-wise manner.
Example 11 Synthesis of FORMULA I (Figure 8)
Synthesis of Compound 1 ((lS,5R)-3-((8-methyl-4-oxo-3,4- dihydroquinazolin - 2-yl) methyl)-l,2,3,4, 5, 6-h exahydro-8H- 1, 5-meth anopyrido[ l,2-a][l, 5 ] diazocin-8-one) :
A mixture of 2-(chloromethyl)-8-methylquinazolin-4(3H)-one (0.208 g, lmmol), (-) cytisine (0.380 g, 2mmol) and K2C03 (0.552 g, 4 mmol) in dry DMF (8 mL) was stirred for 24 h at room temperature and then the reaction was terminated by LC-MS control. Reaction mixture was concentrated under pressure. Then it washed with brine solution and dried with Na2S04 and filtrated.
LCMS m/z :[M+H], found 363. C21H22N4O2 requires 362,43 .
Synthesis of Compound 2 (lS,5R)-3-((4-chloro-8-methylquinazolin-2- yl)methyl)-l,2,3,4,5,6-hexahydro-8H-l,5-methanopyrido[l,2-a][l,5]diazocin-8- one :
Excess amount of POC13 (3 mL) was added dropwise to Compound 1 (0.363 g, lmmol) and the mixture was refluxed for overnight. Reaction mixture was concentrated under pressure. The residue was washed with 10% aqueous NaHC03 solution and dried to obtain compound 2.
LCMS m/z :[M+H], found 381. C21H21C1N4O requires 380,88.
Synthesis of FORMULA I (lS,5R)-3-((4-(benzo[d][l,3]dioxol-5-ylamino)-8- methylquinazolin-2-yl)methyl)-l,2,3,4,5,6-hexahydro-8H-l,5-methanopyrido [1,2-a] [l,5]diazocin-8-one:
A mixture of Compund 2 (0.381 g, lmmol), 3,4-(Methylenedioxy)aniline (0.274 g, 2mmol) and K2C03 (0.552 g, 4 mmol) ) in dry DMF (8 mL) was stirred for 24 h at room temperature and then the reaction was terminated by LC-MS control. Reaction mixture was concentrated under pressure. Then it washed with brine solution and dried with Na2S04 and fdtrated. Then the solvent was evaporated in a rotary evaporator. LCMS m/z :[M+H], found ? C28H27N5O3 requires 481,56
Results
Identification of the Molecule Effect on the Half-Life of the CRYl/2
The stabilization and degradation mechanism of CRY by ubiquitination is an important factor affecting the pace of the mammalian circadian clock. Therefore, we focused on CRY and FBXL3/21 interaction sites for the identification of small molecules stabilizing CRYs. Small molecules with highest binding energies were identified by molecular docking studies on the CRY 1/2 and FBXL3/21 interaction sites. Initially, the mouse CRY1 (mCRYl) structure (PDB ID: 4K0R) was subjected to molecular simulation was performed on CRY1 to bring the structure near their physiological conditions as follow: After structure of CRY1 was solvated in a rectangular box and neutralized with counter ions, the system was minimized, heated up to physiological temperature (310°K) and simulated for 10ns. Root mean square deviation (RMSD) of backbone atoms showed
convergence after initial increase upon minimization. The last frame of the simulation was utilized as the receptor for the docking analysis. Commercially available small molecule libraries with non-identified function were used as ligands. AutoDock Vina was used to screen approximately 2 million commercially available small molecules filtered by “Lipinski’s Rule of Five”. A final number of 32 compounds with affinities ranging from -9 to -13.5 kcal/mol were then tested experimentally.
The toxicity of these top 32 molecules were evaluated on cells prior to in vitro screening using U2-OS cells by MTT at the dose of 20 mM. The small molecule doses yielding more than 90% cell viability were selected for further characterization. The 20 molecules were identified to be nontoxic at given concentration and selected for further characterization.
Effect of FORMULA I on Half-life of Crytpochrome 1 and 2
The effect of the TW68 on CRY1 and CRY2 half-life was assessed using CRY1- dLuc and CRY2-dLuc as dose dependent manner. Plasmids, contains Cryl and Cry2 genes fused with destabilized Luciferase genes, were transfected to HEK 293T cells. The cells treated with TW68 and cycloheximide inhibit protein synthesis. The samples were incubated for 16 hours in Synergy to be able to calculate half-life of luciferases based on bioluminance decay. Analysis of the results indicated that TW68 increased the half-life of CRYs in dose dependent manner.
Effect of FORMULA I on Circadian Rhythm
The effect of the TW68 on circadian clock was further investigated using U2-OS and NIH 3T3 cells stably expressing dLuc reporter, under the Bmall and Per2 promoters, respectively. Cells treated with TW68 had longer periods compared to control. TW68 lengthens period about 3 hours in U2-OS and about 2.6 hours in
NIH 3T3 cells. Further analysis of amplitude in both cell lines in the presence of the TW68 revealed that the molecules also reduced the amplitude.
Effect of FORMULA I on Protein Levels
To assess the effect of the TW68 at biochemical level U2-OS cells treated with molecules. After preparation of cell lysate from U2-OS cells treated with molecule and DMSO, samples were subjected to the SDS-PAGE followed by Western blot analysis using anti-CRYl, anti-CRY2 and anti-PER2. Analysis of the result indicated that both CRY1 and CRY2 levels were higher in the cells in dose dependent manner compared to cells treated with DMSO control. This result suggested that TW68 stabilized both CRYs, which is in agreement with Cryl- dLuc and Cry2-dLuc assay.
Effect of FORMULA I on ntRNA Levels
The effect TW68 on transcription of clock output genes using U2-OS cells. U20S cells were treated with TW68 and DMSO and levels of clock genes transcripts were determined by RT-qPCR. The mRNA levels measured genes were normalized with respect to RplpO gene expression because its expression level is independent from circadian genes. In agreement with stabilization of CRYs proteins, TW68 treatment resulted in significant decrease of Cryl, Cry2, Per2, Dbp and Rev-erba expression in a dose-dependent manner. Furthermore, there was no significant effect of TW68 treatment on Bmall and Clock expression. These results are consistent with the effects of CRYl and CRY2 stabilization since CRY-PER heterodimer represses the expression of E-box regulated circadian genes.
Effects of FORMULA I on Gluconeogenesis
It has been shown that stabilization of CRY s by stabilizer molecule would reduce glucagon-mediated gluconeogenesis via its interaction with Gsa subunit of heterotrimeric G-protein (16). In order to test the effects of TW68 on glucagon-
induced gluconeogenesis, HepG2 cells treated with TW68 and the transcriptional level of the glucagon-induced Pckl and G6pc genes, key genes in gluconeogenesis, were measured. Pckl and G6pc significantly reduced upon exposure TW68. We expected that glucose production in this cell line would reduce upon treatment of TW68. We, therefore, measured glucose level secreted from this cell line and results indicated that glucose levels were decreased dose- dependently. Overall, these results indicate that TW68 acts by stabilizing CRYs and subsequently reducing glucagon-mediated gluconeogenesis.
Effect of FORMULA I in Cryl-/-/Cry2-/~ Mouse Embryonic Fibroblast Cells To eliminate the possibility of TW68 might affect other proteins and, in turn, circadian rhythmicity we tested the effect of these molecule in CryP/Cry2/ mouse embryonic fibroblast cells (DKO-MEF), generated by Udea group (21), transfected with mPer2-dluc plasmid. Results indicated that TW68 had no effect on luminance in dose dependent manner in the absence of the CRY s and suggest that effect of TW68 was through CRYs.
REFERENCES
[1]. Hirano, A., Yumimoto, K., Tsunematsu, R., Matsumoto, M., Oyama, M.,
Kozuka-Hata, H., Nakagawa, T., Lanjakomsiripan, D., Nakayama, Keiichi I., and Fukada, Y. (2013). FBXL21 Regulates Oscillation of the Circadian Clock through Ubiquitination and Stabilization of Cryptochromes. Cell 152, 1106-1118.
[2]. Yoo, S.H., Mohawk, J.A., Siepka, S.M., Shan, Y., Huh, S.K., Hong, H.K.,
Komblum, I., Kumar, V., Koike, N., Xu, M., et al. (2013). Competing E3 ubiquitin ligases govern circadian periodicity by degradation of CRY in nucleus and cytoplasm. Cell 152, 1091-1105.
[3]. Takahashi, J. S. , Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet 18, 164-179 (2017).
[4]. Chen, Z., Yoo, S.H., Park, Y.S., Kim, K.H., Wei, S., Buhr, E., Ye, Z.Y.,
Pan, H.L., and Takahashi, J.S. (2012). Identification of diverse modulators of central and peripheral circadian clocks by high-throughput chemical screening. P Natl Acad Sci USA 109, 101-106.
[5]. Hirota, T., Lee, J.W., St John, P.C., Sawa, M., Iwaisako, K., Noguchi, T.,
Pongsawakul, P.Y., Sonntag, T., Welsh, D.K., Brenner, D.A., et al. (2012). Identification of Small Molecule Activators of Cryptochrome. Science 337, 1094-1097.
[6]. Hirota, T., Lewis, W., Liu, A., Lee, J., Schultz, P., and Kay, S. (2008). A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3beta. Proc Natl Acad Sci USA 105, 20746-20751.
[7]. Lee, J.H., and Sancar, A. (2011). Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis. Proceedings of the National Academy of Sciences 108, 10668.
[8]. Solt, L.A., Wang, Y.J., Baneqee, S., Hughes, T., Kojetin, D.J., Lundasen,
T., Shin, Y., Liu, J., Cameron, M.D., Noel, R., et al. (2012). Regulation of
circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 485, 62-68.
[9]. Lee, J. W., A Small Molecule Modulates Circadian Rhythms through
Phosphorylation of the Period Protein. Angew Chem Int Edit 50, 10608- 10611 (2011).
[10]. Trump, R. P. et al., Optimized Chemical Probes for REV-ERBa. Journal of
Medicinal Chemistry 56, 4729-4737 (2013).
[11]. He, B. et al., The Small Molecule Nobiletin Targets the Molecular
Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome. Cell Metabolism 23, 610-621 (2016).
[12]. Kumar et al., Identification of SR3335 (ML-176): A Synthetic RORa
Selective Inverse Agonist. ACS Chemical Biology 6, 218-222 (2011).
[13]. Czama, A., Bemdt, A., Singh, H.R., Grudziecki, A., Ladumer, A.G.,
Timinszky, G., Kramer, A., and Wolf, E. (2013). Structures of Drosophila Cryptochrome and Mouse Cryptochrome 1 Provide Insight into Circadian
Function. Cell 153, 1394-1405.
[14]. Xing, W.M., Busino, L., Hinds, T.R., Marionni, S.T., Saifee, N.H., Bush,
M.F., Pagano, M., and Zheng, N. (2013). SCFFBXL3 ubiquitin ligase targets cryptochromes at their cofactor pocket. Nature 496, 64-+. [15]. Oshima, T., Yamanaka, I., Kumar, A., Yamaguchi, J., Nishiwaki-Ohkawa,
T., Muto, K., Kawamura, R., Hirota, T., Yagita, K., Irle, S., et al. (2015). C- H activation generates period-shortening molecules that target cryptochrome in the mammalian circadian clock. Angew Chem Int Ed Engl 54, 7193- 7197. [16]. Zhang EE, Liu Y, Dentin R, Pongsawakul PY, Liu AC, Kay SA, et al.
Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis. Nature Medicine. 2010; 16(10): p. 1152-1156.
[17]. Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., and Olson, A.J. (2009). AutoDock4 and AutoDockTools4:
Automated docking with selective receptor flexibility. J Comput Chem 30, 2785-2791.
[18]. Trott, O., and Olson, A.J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31, 455-461.
[19]. Machicao F, Peter A, Machann J, Konigsrainer I, Bohm A, Lutz SZ, Heni
M, Fritsche A, Schick F, Konigsrainer A el al (2016) Glucose-Raising Polymorphisms in the Human Clock Gene Cryptochrome 2 (CRY2) Affect Hepatic Lipid Content. Plos One 11: e0145563. [20]. Dupuis J, Langenberg C, Prokopenko I, New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Gen. 2010;42: 105-16; Kelly MA, Rees SD, Hydrie MZ. Circadian gene variants and susceptibility to type 2 diabetes: a pilot study. PLoS One. 2012
[21]. Ukai-Tadenuma, M.; Yamada, R. G.; Xu, H. Y.; Ripperger, J. A.; Liu, A. C.; Ueda, H. R., Delay in Feedback Repression by Cryptochrome 1 Is
Required for Circadian Clock Function. Cell 2011, 144 (2), 268-281)
[22]. Nangle SN, Rosensweig C, Koike N, Takahashi JS, Green CB, Zheng N, et al. Molecular assembly of the period-cryptochrome circadian transcriptional repressor complex. Elife. 2014; 3: p. e03674.
Claims
1. A CRY -binding compound having the following formula:
for use as a medicament.
2. The compound according to claim 1 for use in the treatment and/or prevention of diseases or disorders associated with the circadian rhythm.
3. The compound according to claim 1 for use in the treatment and/or prevention of diseases or disorders related to CRYl/2.
4. The compound for use according to claim 2 or 3, wherein the disease or disorder is diabetes.
5. The compound for use according to claim 4, wherein the disease or disorder is type 2 diabetes mellitus.
6. The use of a CRY-binding compound having the following formula or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treatment and/or prevention of diseases or disorders associated with the circadian rhythm,
7. Use of a compound according to claim 6 for the preparation of a medicament useful in the treatment and/or prevention of diseases or disorders related to CRY 1/2.
8. Use of a compound according to claim 7, wherein the disease or disorder is diabetes.
9. Use of a compound according to claim 8, wherein the disease or disorder is type 2 diabetes mellitus.
10. A pharmaceutical composition comprising a CRY-binding compound having the following formula:
and at least one pharmaceutical carrier for use as a medicament.
11. A pharmaceutical composition according to claim 10 for use in the treatment and/or prevention of diseases or disorders associated with the circadian rhythm.
12. A pharmaceutical composition according to claim 11 for use in treatment and/or prevention of diseases or disorders related to CRYl/2.
13. A pharmaceutical composition for use according to claim 12 wherein the disease or disorder is diabetes.
14. A pharmaceutical composition for use according to claim 13 wherein the disease or disorder is type 2 diabetes mellitus.
15. A pharmaceutical composition for use according to claim 14, wherein the compound is in a therapeutically effective amount.
16. A method for identifying a compound that stabilize CRYl/2, wherein the method comprises contacting a compound with CRY 1 and CRY2 proteins under conditions allowing for the interaction, and determining whether the compound leads to increase in CRY 1/2 level by using a system that uses a signal and/or a marker generated by the interaction between CRY 1/2 and the compound to detect presence or absence or change of the signal and/or the marker.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2021/050513 WO2022255955A1 (en) | 2021-05-31 | 2021-05-31 | ((1s,9s)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl} -7,11-diazatricyclo[7.3.1.0~2,7~]trideca-2,4-dien-6-one) as a stabilizer of crys for the treatment of circadian rhythm associated diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4346833A1 true EP4346833A1 (en) | 2024-04-10 |
Family
ID=76730974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21736769.7A Pending EP4346833A1 (en) | 2021-05-31 | 2021-05-31 | ((1s,9s)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl} -7,11-diazatricyclo[7.3.1.0~2,7~]trideca-2,4-dien-6-one) as a stabilizer of crys for the treatment of circadian rhythm associated diseases and disorders |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4346833A1 (en) |
WO (1) | WO2022255955A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010108195A1 (en) | 2009-03-20 | 2010-09-23 | The Salk Institute For Biological Studies | Methods for modulating metabolic and circadian rhythms |
-
2021
- 2021-05-31 WO PCT/TR2021/050513 patent/WO2022255955A1/en active Application Filing
- 2021-05-31 EP EP21736769.7A patent/EP4346833A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022255955A1 (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Phuan et al. | Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators | |
Chen et al. | 5-Cyano-6-oxo-1, 6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP | |
KR102453519B1 (en) | Inhibitors of human ezh2, and methods of use thereof | |
AU2014272856B2 (en) | Chemical compounds | |
Pytel et al. | Tumor progression and the different faces of the PERK kinase | |
JP2015509536A (en) | 2-Amino, 6-phenyl-substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors | |
US20120134985A1 (en) | Methods for modulating metabolic and circadian rhythms | |
Cato et al. | Differential modulation of nuclear receptor LRH-1 through targeting buried and surface regions of the binding pocket | |
Wang et al. | Novel functions of cytoplasmic aminoacyl-tRNA synthetases shaping the hallmarks of cancer | |
Wang et al. | RNA binding protein SAMD4: current knowledge and future perspectives | |
EP4346833A1 (en) | ((1s,9s)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl} -7,11-diazatricyclo[7.3.1.0~2,7~]trideca-2,4-dien-6-one) as a stabilizer of crys for the treatment of circadian rhythm associated diseases and disorders | |
CN110950869B (en) | Preparation method and application of multi-target inhibitor acting on QC and GSK-3 beta | |
Surme et al. | TW68, cryptochromes stabilizer, regulates fasting blood glucose levels in diabetic ob/ob and high fat-diet-induced obese mice | |
Lacher et al. | An antioxidant response element regulates the HIF1α axis in breast cancer cells | |
JP2020508675A (en) | Methods for predicting the effects of CDC7 inhibitors | |
JP2011036143A (en) | Medicine for body dysrhythmia and method for screening the same | |
EP2409152A1 (en) | Methods for modulating circadian rythms | |
EP4065100B1 (en) | Destabilizer of cry1 for the treatment of circadian rhythm associated diseases and disorders | |
Du et al. | Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases | |
CN110483432A (en) | A kind of acrylic compounds and preparation method thereof, pharmaceutical composition and purposes | |
Surme et al. | TW68, Cryptochromes stabilizer, regulates fasting blood glucose level in ob/ob and fat-induced diabetic mice | |
US20230078642A1 (en) | 2-[2-({12,12-dimethyl-4-oxo-6-phenyl-3,11-dioxatricyclo[8.4.0.0,2,7]tetradeca-1,5,7,9-tetraen-8-yl}oxy)acetamido]benzamide and derivatives as inhibitor of clock:bmal1 interaction for the treatment of circadian rhythm diseases and disorders | |
Madoux et al. | Small molecule inhibitors of Wee1 degradation and mitotic entry | |
Rosenthal et al. | Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia | |
Li | Unravelling multiple clock mechanisms in vertebrates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20231211 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |